AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15333799 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive protocol (n = 20)
Number of subjects: 45
Study 15333799 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (n = 19)
Number of subjects: 45
Study 10884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 49
Study 10884455 — intervention group
Group type: COMPARATOR
Intervention: Patching
Number of subjects: 49
Study 9356091 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 0.1 mg/kg I.V. plus saline
Number of subjects: 100
Study 9356091 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1 mg/kg I.V. plus saline
Number of subjects: 100
Study 9356091 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 0.1 mg/kg I.V. plus lidocaine 1 mg/kg I.V.
Number of subjects: 100
Study 9356091 — intervention group
Group type: COMPARATOR
Intervention: saline plus saline (control)
Number of subjects: 100
Study 8108605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stimulation (reading, performing mental arithmetic, playing a hand-held 'Nintendo' game)
Number of subjects: 5
Study 8108605 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting
Number of subjects: 5
Study 8108605 — intervention group
Group type: COMPARATOR
Intervention: Mental stimulation
Number of subjects: 5
Study 3954370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide (2 mg/kg x 4: H)
Number of subjects: 0
Study 3954370 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose metoclopramide (1 mg/kg x 4: M)
Number of subjects: 0
Study 28434131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated instruction (conceptual Why and procedural How knowledge)
Number of subjects: 30
Study 28434131 — intervention group
Group type: COMPARATOR
Intervention: Unintegrated instruction (procedural How instruction only)
Number of subjects: 30
Study 28434131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated instruction
Number of subjects: 30
Study 27526655 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage at -20 cm H2O
Number of subjects: 254
Study 27526655 — intervention group
Group type: COMPARATOR
Intervention: Nonsuction drainage
Number of subjects: 254
Study 24808482 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly context-appropriate child-centered counseling (CCC)
Number of subjects: 18
Study 24808482 — intervention group
Group type: COMPARATOR
Intervention: Improved corn-soy blend (CSB++)
Number of subjects: 18
Study 24808482 — intervention group
Group type: COMPARATOR
Intervention: Locally produced ready-to-use supplementary food (RUSF)
Number of subjects: 18
Study 24808482 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC
Number of subjects: 18
Study 24808482 — intervention group
Group type: COMPARATOR
Intervention: CSB++ and RUSF
Number of subjects: 18
Study 23890316 — intervention group
Group type: EXPERIMENTAL
Intervention: All Children in Focus program (intervention group)
Number of subjects: 600
Study 23890316 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 600
Study 21251896 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of MET (n = 19) for 4 weeks followed by 100 mg MET for 4 weeks
Number of subjects: 41
Study 21251896 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of NEB (n = 22) for 4 weeks followed by 10 mg NEB for 4 weeks
Number of subjects: 41
Study 18494632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coban 2 Layer Compression System
Number of subjects: 81
Study 18494632 — intervention group
Group type: COMPARATOR
Intervention: Profore Compression System
Number of subjects: 81
Study 16253414 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (initial dose of 12.5-25mg)
Number of subjects: 42
Study 16253414 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (uniform initial dose of 5mg)
Number of subjects: 42
Study 14649341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.25% plus intravenous morphine 2 mg
Number of subjects: 90
Study 14649341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.25%
Number of subjects: 90
Study 14649341 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 90
Study 10988107 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride
Number of subjects: 11
Study 10988107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9007717 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose UDCA (10 mg kg‐1 day‐1) at bed time
Number of subjects: 27
Study 9007717 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose UDCA (10 mg kg‐1 day‐1) in three divided doses with meals
Number of subjects: 27
Study 1829918 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA/ARA
Number of subjects: 255
Study 1829918 — intervention group
Group type: COMPARATOR
Intervention: DNR/ARA
Number of subjects: 255
Study 6751536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac 100 mg four times a day for one week
Number of subjects: 40
Study 6751536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31682976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir administered during MMC phase II
Number of subjects: 6
Study 31682976 — intervention group
Group type: COMPARATOR
Intervention: Fosamprenavir administered during MMC phase I
Number of subjects: 6
Study 31159753 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) program
Number of subjects: 1254
Study 31159753 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 1254
Study 28624486 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (0 risk factors)
Number of subjects: 34736
Study 28624486 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (1 risk factor)
Number of subjects: 34736
Study 28624486 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (2 risk factors)
Number of subjects: 34736
Study 28624486 — intervention group
Group type: COMPARATOR
Intervention: 3 or 4 risk factors
Number of subjects: 34736
Study 26422605 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 69
Study 23863224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted activating performance feedback strategy
Number of subjects: 25552
Study 23863224 — intervention group
Group type: COMPARATOR
Intervention: Standard quarterly benchmark reports
Number of subjects: 25552
Study 22562389 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab injections
Number of subjects: 18
Study 22562389 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular glucocorticoid injections
Number of subjects: 18
Study 18618363 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpifix
Number of subjects: 30
Study 18618363 — intervention group
Group type: COMPARATOR
Intervention: Dummy
Number of subjects: 30
Study 17365463 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) for detecting deep myometrial invasion
Number of subjects: 101
Study 17365463 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) for detecting cervical invasion
Number of subjects: 101
Study 17365463 — intervention group
Group type: COMPARATOR
Intervention: Histopathologic evaluation (as control)
Number of subjects: 101
Study 15471824 — intervention group
Group type: EXPERIMENTAL
Intervention: Coregistration of SPECT and CT-derived attenuation maps
Number of subjects: 140
Study 15471824 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative analysis
Number of subjects: 140
Study 11718167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 300
Study 11718167 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 300
Study 11718167 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin and triptorelin
Number of subjects: 300
Study 10205747 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele frequency in type 2 DM patients with MI (64%)
Number of subjects: 75
Study 10205747 — intervention group
Group type: EXPERIMENTAL
Intervention: DD homozygotes prevalence in type 2 DM patients with MI (41%)
Number of subjects: 75
Study 10205747 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele (RR 1.43)
Number of subjects: 75
Study 10205747 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype (RR 1.75)
Number of subjects: 75
Study 8172482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (300 mg/day after a loading dose of 900 mg on D1, 500 mg on D2 and D3)
Number of subjects: 208
Study 8172482 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (360 mg/day)
Number of subjects: 208
Study 3075350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg) and artemether (600 mg by injection, 200 mg initially and 100 mg every 12 h)
Number of subjects: 60
Study 3075350 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg/kg orally every 8 h for 7 d)
Number of subjects: 60
Study 31470444 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT plus high-dose edoxaban (60 mg once daily)
Number of subjects: 75
Study 31470444 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT plus low-dose edoxaban (30 mg once daily)
Number of subjects: 75
Study 31470444 — intervention group
Group type: COMPARATOR
Intervention: DAPT only
Number of subjects: 75
Study 30223728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light-intensity exercise while standing every 30 min
Number of subjects: 19
Study 30223728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3 min of walking every 30 min
Number of subjects: 19
Study 30223728 — intervention group
Group type: COMPARATOR
Intervention: Sitting for 8 h uninterrupted
Number of subjects: 19
Study 28827258 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) administered via enema, two times per week for 6 weeks.
Number of subjects: 50
Study 28827258 — intervention group
Group type: COMPARATOR
Intervention: Normal saline control administered via enema, two times per week for 6 weeks.
Number of subjects: 50
Study 28827258 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 50
Study 25618566 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the primary auditory cortex (2 mA for 20 min)
Number of subjects: 12
Study 25618566 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (no stimulation except initial ramp-up for 30 s)
Number of subjects: 12
Study 24366792 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral locking plate
Number of subjects: 40
Study 24366792 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 40
Study 21628697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 146
Study 21628697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 146
Study 21628697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 19108787 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/d
Number of subjects: 1196
Study 19108787 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/d
Number of subjects: 1196
Study 19108787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1196
Study 16634956 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen arginine
Number of subjects: 64
Study 16634956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 14525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential multifactorial cardiac rehabilitation
Number of subjects: 132
Study 14525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient multifactorial rehabilitation
Number of subjects: 132
Study 14525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 132
Study 14525716 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary rehabilitation
Number of subjects: 132
Study 10858985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (preinhalation)
Number of subjects: 12
Study 10858985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, preinhalation)
Number of subjects: 12
Study 8826510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg) + bromazepan (3 mg)
Number of subjects: 164
Study 8826510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg) + placebo
Number of subjects: 164
Study 8826510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepan (3 mg) + placebo
Number of subjects: 164
Study 8826510 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 164
Study 1425546 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session prevention program
Number of subjects: 3153
Study 1425546 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 3153
Study 6731021 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350 mg I/ml
Number of subjects: 40
Study 6731021 — intervention group
Group type: COMPARATOR
Intervention: Urografin 370 mg I/ml
Number of subjects: 40
Study 30251154 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected weight-bearing as tolerated
Number of subjects: 115
Study 30251154 — intervention group
Group type: COMPARATOR
Intervention: Protected weight-bearing
Number of subjects: 115
Study 30251154 — intervention group
Group type: COMPARATOR
Intervention: Unprotected non-weight-bearing
Number of subjects: 115
Study 31126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica dioica 450 mg/day and acupuncture 11 sessions (A)
Number of subjects: 72
Study 31126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo (B)
Number of subjects: 72
Study 31126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture and Urtica dioica (C)
Number of subjects: 72
Study 31126551 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and placebo (D)
Number of subjects: 72
Study 27601217 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4g/day)
Number of subjects: 23
Study 27601217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose, same dosage)
Number of subjects: 23
Study 27601217 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Number of subjects: 23
Study 27601217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27601217 — intervention group
Group type: COMPARATOR
Intervention: Beta-alanine and Placebo
Number of subjects: 23
Study 25816342 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine plus safe storage
Number of subjects: 1800
Study 25816342 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe storage
Number of subjects: 1800
Study 25816342 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1800
Study 24004044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump (SAP)
Number of subjects: 60
Study 24004044 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60
Study 24004044 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 60
Study 21726440 — intervention group
Group type: EXPERIMENTAL
Intervention: HIP Programme
Number of subjects: 0
Study 21726440 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 19236409 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole Limpet Hemocyanin (KLH) 100 microg adsorbed to aluminium hydroxide
Number of subjects: 32
Study 19236409 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyhole Limpet Hemocyanin (KLH) 10 microg intra-dermally
Number of subjects: 32
Study 19236409 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (alum alone)
Number of subjects: 32
Study 16930768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 263
Study 16930768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 14644857 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and NSAIDs
Number of subjects: 76
Study 12785090 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Four four-layer bandage system
Number of subjects: 10
Study 8831474 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow splinting only (Group A)
Number of subjects: 10
Study 8831474 — intervention group
Group type: COMPARATOR
Intervention: Local steroid injection plus elbow splinting (Group B)
Number of subjects: 10
Study 1429485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day, 40 mg/day, 60 mg/day)
Number of subjects: 51
Study 1429485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 4043661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacitracin (80,000 U/day)
Number of subjects: 42
Study 4043661 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg/day)
Number of subjects: 42
Study 4043661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study 31254431 — intervention group
Group type: EXPERIMENTAL
Intervention: C-SVEST scale
Number of subjects: 1442
Study 30520413 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified self‐management plan advising temporary quadrupling of inhaled corticosteroid dose
Number of subjects: 1922
Study 30520413 — intervention group
Group type: COMPARATOR
Intervention: Usual-care self‐management plan
Number of subjects: 1922
Study 30520413 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified self‐management plan
Number of subjects: 1922
Study 27255079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 400
Study 27255079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 25283697 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN‐XR
Number of subjects: 103
Study 25283697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 22760494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 135
Study 22760494 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 135
Study 20578203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes identified by fasting plasma glucose (FPG) alone
Number of subjects: 1677
Study 20578203 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT) at baseline
Number of subjects: 1677
Study 20578203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors measured (elevated A(1c), 2‐h PG, fasting insulin (FI), albuminuria, obesity)
Number of subjects: 1677
Study 20578203 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, elevated FI, less physical activity
Number of subjects: 1677
Study 18037602 — intervention group
Group type: EXPERIMENTAL
Intervention: AIME (Integrated Medical Encounter)
Number of subjects: 120
Study 18037602 — intervention group
Group type: COMPARATOR
Intervention: non-AIME (control group)
Number of subjects: 120
Study 15921608 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi vaccine
Number of subjects: 96476
Study 15921608 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal A vaccine
Number of subjects: 96476
Study 11813173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic G-CSF administration after chemotherapy intensification
Number of subjects: 46
Study 11813173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 46
Study 10400415 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF at a dose of 3 microg/kg s.c. on days 1‐2, rhEpo at a dose of 60 U/kg s.c. on days 3‐5, repeated for a total of 6 weeks, with dose increase to 120 U/kg if Hb rise not achieved.
Number of subjects: 19
Study 7740017 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based smoking cessation intervention in Den Bosch
Number of subjects: 1093
Study 7740017 — intervention group
Group type: COMPARATOR
Intervention: Control city (Apeldoorn)
Number of subjects: 1093
Study 2044550 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 21
Study 2044550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7267677 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine (100 mg per day)
Number of subjects: 26
Study 7267677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31060591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (RA)
Number of subjects: 148
Study 31060591 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 148
Study 27697911 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (intoxicated)
Number of subjects: 41
Study 27697911 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 41
Study 26388707 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (S; 100 mg)
Number of subjects: 12
Study 26388707 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine)
Number of subjects: 12
Study 26388707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 26388707 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 12
Study 23903811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine dose reduction (20% reduction weekly for 10 weeks)
Number of subjects: 15
Study 23903811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in morphine dose)
Number of subjects: 15
Study 20963533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic THAs
Number of subjects: 512
Study 20963533 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene THAs
Number of subjects: 512
Study 19712598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention programme
Number of subjects: 185
Study 19712598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study 17439439 — intervention group
Group type: EXPERIMENTAL
Intervention: INFANIB screening tool
Number of subjects: 6150